Press release
ICON Releases Expanded End-to-end Clinical Trial Tokenisation Solution
Solution seamlessly delivers proprietary technology, real world data and analytics, aligning to industry security and data privacy standards
About this update from Icon Plc
[{"type":"text","content":"\nSolution seamlessly delivers proprietary technology, real world data and analytics, aligning to industry security and data privacy standards\n\n\n DUBLIN--(BUSINESS WIRE)--\nICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announces the release of its next generation Clinical Trial Tokenisation solution. The combination of ICON’s proprietary tokenisation engine, access to real-world data and advanced clinical analytics expertise, now delivered through a cohesive and seamless operational model, provides valuable, long-term insights on drug safety and efficacy, throughout the product development lifecycle.\n\n\nICON’s next generation proprietary Clinical Trial Tokenisation solution seamlessly integrates all the necessary components to allow for the collation of patient data in a consented, discreet and non-intrusive way with Privacy Protected Record Linkage (PPRL) across time and source. Furthermore, ICON’s capability to generate multiple tokens, coupled with advanced analytics, provides highly accurate matching (up to ~90%) of clinical trial participants to the largest ecosystem of real-world data sources in the United States. This enables the best available secondary data to be used, resulting in enhanced evidence generation in a highly cost and time efficient manner for our customers, with robust protection of patient privacy.\n\n\nValuable insights from this offering can be leveraged in many ways, including regulatory and reimbursement discussions and scientific publications to optimise clinical development lifecycles. This can also be used to better understand the response of specific sub-cohorts of patients, and to conduct long-term safety surveillance.\n\n\nICON’s Clinical Trial Tokenisation solution is delivered within an operating framework aligned to industry security and data privacy standards, and its corporate security and data protection programs have been assessed to ISO 27001 and 27701 standards.\n\n\nSteve Cutler, CEO, ICON commented: “As an early pioneer of clinical trial tokenisation, ICON fully understands the potential it has to transform clinical development. This enhanced integrated offering enables customers to leverage powerful analytics in an efficient and cost-effective manner for greater understanding and insights of trends in disease, indicati...